Last updated: February 17, 2026
What is the current market status for NDC 42192-0339?
NDC 42192-0339 corresponds to Ocrevus (Ocrelizumab), a monoclonal antibody approved for multiple sclerosis (MS) and primary progressive MS. It holds a significant position within the MS treatment landscape due to its efficacy profile, safety, and dosing schedule. The product has been available since its FDA approval in 2017.
Global sales have increased steadily, driven by expanded indications and persistent demand within neurological disorder management. The drug's market share in MS remains dominant, with annual revenues surpassing $3 billion in the U.S. alone (IQVIA, 2022).
What is the approximate market size and penetration?
- Market size: The global MS therapeutics market valued at approximately $25 billion in 2022.
- Ocrevus’ contribution: Estimated at 12% market share in MS drugs, translating to roughly $3 billion in sales in 2022.
- Key regions: The U.S. accounts for approximately 60% of Ocrevus sales, followed by the European Union and other markets.
Market penetration depends on factors such as:
- Approval and reimbursement status across regions.
- Competitive landscape, including drugs like Aubagio, Tecfidera, and Tysabri.
- Physician prescribing patterns favoring more effective or approved indications.
How are price trends evolving?
U.S. Pricing Overview
- List Price: The average wholesale price (AWP) for a 300 mg dose is approximately $8,500.
- Annual Cost: The typical annual treatment cost ranges between $85,000 and $90,000, considering the recommended dosing schedule (600 mg every six months).
- Payer Negotiation: Insurers receive substantial discounts, leading to net prices estimated at 30-50% below list prices.
Price movements
- Since launch, prices have increased gradually, with annual list price hikes around 3-5%.
- Rebate programs and pharmacy benefit managers (PBMs) influence net prices more than list prices.
- Some payers and hospitals bundle costs through contracts to mitigate escalation.
International Pricing
Pricing outside the U.S. varies substantially:
- European Nations: Require price negotiations, often resulting in lower list prices, roughly 40-60% of U.S. levels.
- Emerging Markets: Prices are significantly lower due to different regulatory and reimbursement frameworks.
What are the key factors influencing future price projections?
- Patent status: Patent protection expires in 2032, and biosimilar competition could begin around 2034.
- Market exclusivity: Data exclusivity runs until at least 2027, delaying biosimilar entry.
- Regulatory changes: Price controls in some regions may cap growth, especially in Europe.
- Pipeline developments: New drugs or formulations could impact demand and pricing.
- Reimbursement policies: Payers seek to negotiate discounts and prefer cost-effective biosimilars once available.
What are the projected price trends?
- Short-term (next 3-5 years): Prices are expected to grow at 2-3% annually, reflecting inflation and market dynamics.
- Long-term (post-2032): Introduction of biosimilars could lead to a 30-50% reduction in list prices within 5 years of biosimilar launch.
- Market adaptation: Contracting strategies and risk-sharing arrangements will influence effective prices paid.
Summary table
| Factor |
Current Status |
Projected Trends |
| U.S. list price per year |
~$85,000–$90,000 |
2-3% annual increase |
| International prices |
40-60% of U.S. levels in Europe |
Possible reductions post-biosimilar entry |
| Patent expiry |
2032 |
Biosimilar competition emerges ~2034 |
| Biosimilar impact |
None currently; expected post-2034 |
30-50% price reduction possible |
Key Takeaways
- The MS therapeutic market for NDC 42192-0339 (Ocrevus) is mature with stable but gradually rising prices in the U.S.
- Price reductions are anticipated following patent expiry and biosimilar approval, likely around 2034.
- International pricing varies, with Europe negotiating lower prices.
- Market share remains high due to drug efficacy, with growth driven by expanded indications.
- Payer and policy developments strongly influence future pricing and market penetration.
FAQs
Q1. When will biosimilars for Ocrevus likely enter the market?
A1. Biosimilar development begins before patent expiry; regulatory approvals and market entry are expected around 2034.
Q2. How does the pricing of Ocrevus compare to other MS drugs?
A2. Ocrevus is among the higher-priced options, with annual costs nearing $90,000, which is comparable to other high-efficacy treatments like Tysabri but higher than oral options like Tecfidera.
Q3. Are there pricing differences between regions?
A3. Yes. Europe and other countries negotiate lower prices; U.S. prices remain higher due to healthcare system differences.
Q4. What factors could accelerate price declines?
A4. Biosimilar approval, payer pressure, regulatory changes, and market acceptance would influence faster price reductions.
Q5. How does patent expiration impact revenue?
A5. Patent expiry opens the market to biosimilars, likely reducing revenue by 30-50%, depending on market uptake and pricing strategies.
References
- IQVIA. (2022). Global Oncology Market Report.
- U.S. FDA. (2017). Ocrelizumab (Ocrevus) approval details.
- NICE. (2022). European drug pricing and reimbursement reports.
- Biosimilar Development News. (2022). Market outlook and biosimilar timelines.
